Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
暂无分享,去创建一个
Neta Zach | Jason Walker | Ervin Sinani | Igor Katsovskiy | Merit Cudkowicz | Albert A. Taylor | David L. Ennist | Hagit Alon | Alexander Sherman | Robert Kueffner | Melanie L. Leitner
[1] C. Coffman,et al. Factors associated with survival in the National Registry of Veterans with ALS , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[2] R. Tamura,et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[3] H. Miwa,et al. Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005 , 2008, Journal of Neurological Sciences.
[4] D. Schoenfeld,et al. Functional outcome measures as clinical trial endpoints in ALS , 2004, Neurology.
[5] Loris Zanier,et al. The Incidence of Amyotrophic Lateral Sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: A Retrospective Population-Based Study , 2013, Neuroepidemiology.
[6] Maurizio Fava,et al. Amyotrophic lateral sclerosis disease progression model , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[7] S. Paganoni,et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis , 2012, Journal of Neurology.
[8] M. Turner,et al. Pattern of spread and prognosis in lower limb-onset ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[9] B. Mohammadi,et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression , 2008, Journal of the Neurological Sciences.
[10] V. Drory,et al. Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress? , 2009, Journal of the Neurological Sciences.
[11] Johann S. Hawe,et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression , 2014, Nature Biotechnology.
[12] S. Appel,et al. Amyotrophic lateral sclerosis: early predictors of prolonged survival , 2006, Journal of Neurology.
[13] V. Meininger,et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.
[14] J. Cedarbaum,et al. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials , 1997, Journal of the Neurological Sciences.
[15] B. Levin,et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[16] D. Kuffler,et al. Are there causal relationships between the development of the inflammatory diseases amyotrophic lateral sclerosis and asthma? , 2006, Puerto Rico health sciences journal.
[17] T D Koepsell,et al. Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.
[18] Lucette Lacomblez,et al. Progression in ALS is not linear but is curvilinear , 2010, Journal of Neurology.
[19] E. Beghi,et al. Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[20] A. Pestronk,et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis , 2011, Neurology.
[21] T. Hirayama,et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. , 2012, Internal medicine.
[22] R. Bedlack,et al. Historical controls in ALS trials , 2011, Neurology.
[23] R. Conwit,et al. Infrastructure resources for clinical research in amyotrophic lateral sclerosis , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[24] V. Meininger,et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[25] G. Parry,et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis , 1996, Neurology.
[26] S. Appel,et al. Predictability of disease progression in amyotrophic lateral sclerosis , 2006, Muscle & nerve.
[27] Robert H. Brown,et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS) , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[28] Adriano Chiò,et al. State of play in amyotrophic lateral sclerosis genetics , 2013, Nature Neuroscience.
[29] V. Meininger,et al. How can we improve clinical trials in amyotrophic lateral sclerosis? , 2011, Nature Reviews Neurology.
[30] W. Bradley. A controlled trial of recombinant methionyl human BDNF in ALS , 1999, Neurology.
[31] Jon Neville,et al. Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. , 2013, Journal of Alzheimer's disease : JAD.
[32] Robert G. Miller,et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2007, The Cochrane database of systematic reviews.
[33] M. Naumann,et al. Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.
[34] Richard Robinson,et al. News from the AAN Annual Meeting: ALS Trial Patients Don't Reflect the General ALS Population: A True Treatment Effect May be Elusive , 2011 .
[35] O. Hardiman,et al. Amyotrophic lateral sclerosis , 2011, The Lancet.
[36] S. Reingold,et al. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.
[37] M. Carone,et al. Patients who survive 5 years or more with ALS in Olmsted County, 1925–2004 , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[38] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[39] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[40] D. Schoenfeld,et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis , 2008, Muscle & nerve.
[41] A. Ludolph,et al. Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.
[42] A. Chiò,et al. ALS clinical trials , 2011, Neurology.
[43] T. Conrad,et al. A clinical trial of creatine in ALS , 2004, Neurology.
[44] P. Nichelli,et al. Amyotrophic lateral sclerosis: Prognostic indicators of survival , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[45] E. Beghi,et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[46] Merit E. Cudkowicz,et al. Clinical significance in the change of decline in ALSFRS-R , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[47] Adriano Chiò,et al. Acute migraine treatment with droperidol , 2003, Neurology.
[48] D. Schoenfeld,et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.
[49] G. Filippini,et al. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[50] A. Destée,et al. Phase II/III randomized trial of TCH346 in patients with ALS , 2007, Neurology.
[51] S. Paganoni,et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis , 2011, Muscle & nerve.
[52] Robert H. Brown,et al. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[53] M. Cudkowicz,et al. The PRO-ACT database , 2014, Neurology.
[54] A. Chiò,et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. , 2014, JAMA neurology.
[55] A. Kengne,et al. Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review , 2014, BMC Research Notes.
[56] D. Schoenfeld,et al. Trial of celecoxib in amyotrophic lateral sclerosis , 2006, Annals of neurology.
[57] S. Petri,et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis , 2013, European journal of neurology.